Tasly Pharmaceuticals

As an international modern Chinese medicine enterprise, Tasly Pharma. (Stock code: 600535) is committed to developing into a leading solution provider of medicine and health services with global influence in China. With "people-oriented and precise innovation", Tasly Pharma. constantly promotes the progress of medicine and health to make every human-being can enjoy the beauty and hope of life. Headquartered in Tianjin, China, the company has more than 20 research centers worldwide and 11 production bases throughout the country. We are committed to cracking the digital code of life medicine. Adhering to the concept of "patient-centered", we pay close attention to the evolution of disease spectrum and make precise innovations in major therapeutic fields such as cardio-cerebrovascular, digestion and metabolism, tumor immunity, and neuroscience, which sustain the healthy life experience of human beings. With a rich drug combination including modern Chinese medicine, chemical medicine and biological innovation medicine, regenerative medicine and the 4-D integrated health management solutions, we can provide service of the whole health journey including health examination, early warning, prevention, diagnosis, treatment and rehabilitation and a personalized and integrated medical solutions covering the whole disease course for each patient and family so as to meet the diverse needs of the individual life, optimize life experience and improve life quality. We continue to build an integrated platform of the whole value chain of life health, explore and develop breakthrough therapies to solve unmet clinical needs, empower medical researchers, medical staff and industry partners, and bring multidisciplinary and interdisciplinary medical innovations to the benefit of patients around the world.